Judge rules AstraZeneca's late Seroquel safety data does not confer exclusivity
This article was originally published in Scrip
Executive Summary
AstraZeneca has again struck out in its effort to vacate the more than 10 approvals of US generic versions of its antipsychotic Seroquel (quetiapine fumurate) in late March. A federal judge has rejected the company's bid to overturn the approvals on grounds that they violate the drug maker's marketing exclusivity rights to certain warnings on its label, according to an opinion unsealed on 5 July.